NS-050/NCNP-03 in Boys With DMD (Meteor50)

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 18, 2024

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Duchenne Muscular Dystrophy
Interventions
DRUG

NS-050/NCNP-03

NS-050/NCNP-03 solution for IV infusion.

DRUG

Placebo

NS-050/NCNP-03 placebo-matching solution for IV infusion.

Trial Locations (18)

15213

RECRUITING

University of Pittsburgh Medical Center, Pittsburgh

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

60611

RECRUITING

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

66103

RECRUITING

University of Kansas Medical Center, Kansas City

80011

RECRUITING

Children's Hospital Colorado, Aurora

90027

NOT_YET_RECRUITING

Children's Hospital Los Angeles, Los Angeles

Unknown

NOT_YET_RECRUITING

Alberta Children's Hospital, Calgary

NOT_YET_RECRUITING

British Columbia Children's Hospital, Vancouver

RECRUITING

London Health Sciences Centre, London

RECRUITING

Pusan National University Yangsan Hospital, Yangsan

NOT_YET_RECRUITING

Seoul National University Hospital, Seoul

NOT_YET_RECRUITING

Ankara Bilkent City Hospital, Ankara

NOT_YET_RECRUITING

Istanbul University, Istanbul

NOT_YET_RECRUITING

Yeditepe University Kosuyolu Hospital, Istanbul

502-8558

RECRUITING

National Hospital Organization Nagara Medical Center, Nagara

663-8501

RECRUITING

Hyogo Medical University Hospital, Nishinomiya

560-8552

RECRUITING

NHO Osaka Toneyama Medical Center, Toyonaka

187-8551

RECRUITING

National Center of Neurology and Psychiatry, Kodaira

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Nippon Shinyaku Co., Ltd.

INDUSTRY

lead

NS Pharma, Inc.

INDUSTRY

NCT06053814 - NS-050/NCNP-03 in Boys With DMD (Meteor50) | Biotech Hunter | Biotech Hunter